Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

J Lewis Research Inc

Neither a doctor nor a teaching hospital

Research payments

$42,340,210

5,317 payments

Through program year 2025, J Lewis Research Inc is reported as receiving $42,340,210 in research payments, across 5,317 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,604,429 406
2024 Research $5,142,918 249
2023 Research $5,375,215 1,685
2022 Research $7,902,942 862
2021 Research $9,522,422 971
2020 Research $4,979,593 516
2019 Research $4,812,691 628

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $30,150,531 2,326 payments
  2. Moderna TX, Inc. $10,239,138 2,239 payments
  3. Allergan Inc. $730,349 199 payments
  4. GlaxoSmithKline, LLC. $366,828 238 payments
  5. Teva Pharmaceuticals USA, Inc. $279,437 189 payments
  6. Merck Sharp & Dohme Corporation $118,959 3 payments
  7. AbbVie, Inc. $108,414 42 payments
  8. Beckman Coulter, Inc. $64,301 19 payments
  9. Genentech, Inc. $50,983 4 payments
  10. H. Lundbeck A S $50,944 15 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $7,577,423 202 payments
  2. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $3,214,710 452 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $2,061,454 134 payments
  4. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $1,633,186 93 payments
  5. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $1,570,797 14 payments
  6. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $1,542,794 73 payments
  7. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccinenaive Adults 18 Years of Age and Older $1,496,784 97 payments
  8. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,393,963 1,031 payments
  9. A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $1,347,715 53 payments
  10. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,274,815 65 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record